TY - JOUR
T1 - Primary antiphospholipid syndrome
T2 - A low-grade auto-inflammatory disease?
AU - Ames, P. R.J.
AU - Antinolfi, I.
AU - Ciampa, A.
AU - Batuca, J.
AU - Scenna, G.
AU - Lopez, L. R.
AU - Delgado Alves, J.
AU - Iannaccone, L.
AU - Matsuura, E.
N1 - Funding Information:
Funding: The financial support of Senit Foundation, Scotland, UK is greatly appreciated.
PY - 2008
Y1 - 2008
N2 - Objective. To test the inflammation and immune activation hypothesis in primary thrombotic APS (PAPS) and to identify clinical and laboratory factors related to inflammation and immune activation. Methods. PAPS (n = 41) patients were compared with patients with inherited thrombophilia (IT, n = 44) and controls (CTR, n = 39). IgG aCL, IgG anti-β2-glycoprotein I (β2GPI), high-sensitivity CRP (hs-CRP), serum amyloid A (SAA), CRP bound to oxidized low-density lipoprotein-β2GPI complex (CRP-oxLDL-β2 GPI) (as inflammatory markers) neopterin (NPT), soluble CD14 (sCD14) (as immune activation markers) were measured by ELISA. Results. After correction for confounders, PAPS showed higher plasma levels of hs-CRP (P = 0.0004), SAA (P = 0.01), CRP-oxLDL-β2GPI (P = 0.0004), NPT (P = 0.0001) and sCD14 (P = 0.007) than IT and CTR. Two regression models were applied to the PAPS group: in the first, IgG aCL and IgG β2GPI were included amongst the independent variables and in the second they were excluded. In the first model, SAA (as the dependent variable) independently related to thrombosis number (P = 0.003); NPT (as the dependent variable) independently related to thrombosis type (arterial, P = 0.03) and number (P = 0.04); sCD14 (as the dependent variable) independently related to IgG β2 GPI (P = 0.0001), age (0.001) and arterial thrombosis (P = 0.01); CRP-oxLDL-β2 GPI (as the dependent variable) independently related to IgG β2GPI (P = 0.0001). In the second model, sCD14 and NPT independently related to each other (P = 0.002) (this was noted also in the IT group, P = 0.0001) and CRP-oxLDL-β2GPI independently predicted SAA (P = 0.002). Conclusion. Low-grade inflammation and immune activation occur in thrombotic PAPS and relate to clinical features and aPL levels.
AB - Objective. To test the inflammation and immune activation hypothesis in primary thrombotic APS (PAPS) and to identify clinical and laboratory factors related to inflammation and immune activation. Methods. PAPS (n = 41) patients were compared with patients with inherited thrombophilia (IT, n = 44) and controls (CTR, n = 39). IgG aCL, IgG anti-β2-glycoprotein I (β2GPI), high-sensitivity CRP (hs-CRP), serum amyloid A (SAA), CRP bound to oxidized low-density lipoprotein-β2GPI complex (CRP-oxLDL-β2 GPI) (as inflammatory markers) neopterin (NPT), soluble CD14 (sCD14) (as immune activation markers) were measured by ELISA. Results. After correction for confounders, PAPS showed higher plasma levels of hs-CRP (P = 0.0004), SAA (P = 0.01), CRP-oxLDL-β2GPI (P = 0.0004), NPT (P = 0.0001) and sCD14 (P = 0.007) than IT and CTR. Two regression models were applied to the PAPS group: in the first, IgG aCL and IgG β2GPI were included amongst the independent variables and in the second they were excluded. In the first model, SAA (as the dependent variable) independently related to thrombosis number (P = 0.003); NPT (as the dependent variable) independently related to thrombosis type (arterial, P = 0.03) and number (P = 0.04); sCD14 (as the dependent variable) independently related to IgG β2 GPI (P = 0.0001), age (0.001) and arterial thrombosis (P = 0.01); CRP-oxLDL-β2 GPI (as the dependent variable) independently related to IgG β2GPI (P = 0.0001). In the second model, sCD14 and NPT independently related to each other (P = 0.002) (this was noted also in the IT group, P = 0.0001) and CRP-oxLDL-β2GPI independently predicted SAA (P = 0.002). Conclusion. Low-grade inflammation and immune activation occur in thrombotic PAPS and relate to clinical features and aPL levels.
KW - Anti-phospholipid syndrome
KW - C-reactive protein
KW - Neopterin
KW - Serum amyloid A
KW - Soluble CD14
UR - http://www.scopus.com/inward/record.url?scp=56649123530&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=56649123530&partnerID=8YFLogxK
U2 - 10.1093/rheumatology/ken382
DO - 10.1093/rheumatology/ken382
M3 - Article
C2 - 18930964
AN - SCOPUS:56649123530
SN - 1462-0324
VL - 47
SP - 1832
EP - 1837
JO - Rheumatology
JF - Rheumatology
IS - 12
ER -